Postmarketing safety surveillance: Where does signal detection using electronic healthcare records fit into the big picture?

Drug Safety

Volumn 36, Issue 3, 2013, Pages 183-197

  Coloma, Preciosa M ^a   Trifirò, Gianluca ^a,b   Patadia, Vaishali ^a,c   Sturkenboom, Miriam ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MESSINA   (Italy)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; APROTININ; CERIVASTATIN; CISAPRIDE; DEXTROPROPOXYPHENE; EFALIZUMAB; ETRETINATE; FANOLESOMAB TC 99M; GEMTUZUMAB OZOGAMICIN; LEVACETYLMETHADOL; LUMIRACOXIB; MEDIDIA; NATALIZUMAB; PEMOLINE MAGNESIUM; PERGOLIDE; RAPACURONIUM BROMIDE; RIMONABANT; ROFECOXIB; ROSIGLITAZONE; SIBUTRAMINE; TEGASEROD; THIORIDAZINE; TROGLITAZONE; TROVAFLOXACIN; TURVEL; UNCLASSIFIED DRUG; VALDECOXIB; XIMELAGATRAN;

ADVERSE DRUG REACTION; BIRTH DEFECT; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONSTIPATION; DATA BASE; DEPRESSION; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HUMAN; HYPOTENSION; INFORMATION SYSTEM; ISCHEMIC COLITIS; KIDNEY FAILURE; LIVER FAILURE; MANDATORY REPORTING; MENTAL DISEASE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RESPIRATORY DISTRESS; REVIEW; SIGNAL DETECTION; SKIN MANIFESTATION; SUICIDE; TOXIC HEPATITIS; VALVULAR HEART DISEASE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATA MINING; DATABASES, FACTUAL; DELIVERY OF HEALTH CARE; ELECTRONIC HEALTH RECORDS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOVIGILANCE; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84876575913     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0018-x     Document Type: Review

References (107)

1. Zarin DA, Young JL, West JC. Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. Soc Psychiatry Psychiatr Epidemiol. 2005;40(1):27-35.
2. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162(15):1682-8.
3. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312(7040):1215-8.
4. Papanikolaou PN, Christidi GD, Ioannidis JP. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ. 2006;174(5):635-41.
5. US FDA. FDA issues public health warning on phenylpropanolamine. Available from URL: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ ucm150763.htm. Accessed 9 Jan 2013.
6. US FDA. FDA requires additional labeling for over-the-counter pain relievers and fever reducers to help consumers use products safely. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ ucm149573.htm. Accessed 9 Jan 2013.
7. Cantu C, Arauz A, Murillo-Bonilla LM, et al. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke. 2003;34(7):1667-72.
8. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098.
9. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System. Am Stat. 1999;53:177-202.
10. Almenoff JS, DuMouchel W, Kindman LA, et al. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf. 2003;12(6):517-21.
11. Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf. 2003;26(3):159-86.
12. Bousquet C, Henegar C, Louet AL, et al. Implementation of automated signal generation in pharmacovigilance using a knowledge-based approach. Int J Med Inform. 2005;74(7-8):563-71.
13. Bate A, Edwards IR. Data mining techniques in pharmacovigilance. In: Hartzema AG, Tilson HH, Chan KA, editors. Pharmacoepidemiology and therapeutic risk management. Cincinnati: Harvey Whitney; 2008.
14. Coulter D. Signal generation in the New Zealand Intensive Medicines Monitoring Programme: a combined clinical and statistical approach. Drug Saf. 2002;25(6):433-9.
15. Heeley E, Wilton LV, Shakir SA. Automated signal generation in prescription-event monitoring. Drug Saf. 2002;25(6):423-32.
16. Platt R, Wilson M, Chan KA, et al. The new Sentinel Network: improving the evidence of medical-product safety. N Engl J Med. 2009;361(7):645-7.
17. Coloma PM, Schuemie MJ, Trifiro G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf. 2011;20(1):1-11.
18. World Health Organization. Safety of medicines: a guide to detecting and reporting adverse drug reactions 2002. Available from URL: http://whqlibdoc.who. int/hq/2002/WHO-EDM-QSM-2002.2.pdf Accessed 10 Jul 2011.
19. Report of CIOMS Working Group VIII. Practical aspects of signal detection in pharmacovigilance. Geneva: WHO; 2010.
20. Hauben M, Aronson JK. Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf. 2009;32(2):99-110.
21. US FDA. FDA Adverse Event Reporting System (AERS). Available from URL: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ AdverseDrugEffects/default.htm. Accessed 2013 Jan 9.
22. Vaccine Adverse Event Reporting System. Available from URL: http://vaers.hhs.gov/index/about/index. Accessed 2013 Jan 9.
23. European Medicines Agency. EudraVigilance. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document-listing/ document-listing-000239.jsp&mid=WC0b01ac05800250b5. Accessed 9 Jan 2013.
24. European Medicines Agency. 2009 EudraVigilance-human status report. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Report/ 2010/10/WC500097692.pdf. Accessed 9 Jan 2013.
25. The Uppsala Monitoring Centre. The WHO programme. Available from URL: http://www.who-umc.org/DynPage.aspx?id=98078&mn1=7347&mn2=7252&mn3= 7322. Accessed 20 Apr 2012.
26. Uppsala Monitoring Centre. Uppsala reports, 2012 April. Available from URL: http://www.who-umc.org/graphics/26656.pdf. Accessed 29 May 2012.
27. Piccinni C, Sacripanti C, Poluzzi E, et al. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. Eur J Clin Pharmacol. 2010;66(2):199-206.
28. Koutkias V, Niès J, Jensen S, et al., editors. Patient safety informatics: adverse drug events, human factors, and IT tools for patient medication safety, vol. 166. Studies in health technology and informatics. IOS Press; 2011.
29. Szarfman A, Tonning JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. Pharmacotherapy. 2004;24(9):1099-104.
30. Hauben M, Madigan D, Gerrits CM, et al. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005;4(5):929-48.
31. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoeidemiol Drug Saf. 2001;10(6):483-6.
32. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519-23.
33. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 2002;25(6):381-92.
34. Bate A, Lindquist M, Edwards IR, et al. A data mining approach for signal detection and analysis. Drug Saf. 2002;25(6):393-7.
35. Hauben M, Horn S, Reich L. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions. Drug Saf. 2007;30(2):143-55.
36. Vilar S, Harpaz R, Chase HS, et al. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J Am Med Inform Assoc. 2011;18(Suppl. 1):i73-80.
37. Darpö B. Detection and reporting of drug-induced proarrhythmias: room for improvement. Europace. 2007;9 Suppl. 4:iv23-36.
38. Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis. 1994;18(6):946-50.
39. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165(12):1363-9.
40. US Food and Drug Administration. FDA announces withdrawal fenfluramine and dexfenfluramine. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm. Accessed 18 Oct 2011.
41. Desmond P. Flucloxacillin hepatitis: an Australian epidemic. Aust NZ J Med. 1995;25(3):195-6.
42. Salvo F, Polimeni G, Moretti U, et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother. 2007;60(1):121-6.
43. Thomson JA, Fairley CK, Ugoni AM, et al. Risk factors for the development of amoxycillin-clavulanic acid associated jaundice. Med J Aust. 1995;162(12):638-40.
44. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep. 1999;48(43):1007.
45. Intussusception among recipients of rotavirus vaccine: United States, 1998-1999. MMWR Morb Mortal Wkly Rep. 1999;48(27):577-81.
46. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med. 2001;344(8):564-72.
47. Niu MT, Erwin DE, Braun MM. Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. Vaccine. 2001;19(32):4627-34.
48. Update: Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine: United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep. 2006;55(41):1120-4.
49. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385-96.
50. Friedman MA, Woodcock J, Lumpkin MM, et al. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999;281(18):1728-34.
51. Merck pulls arthritis drug Vioxx from market. Available from URL: http://www.npr.org/templates/story/story.php?storyId=4054991. Accessed 11 Nov 2011.
52. Krumholz HM, Ross JS, Presler AH, et al. What have we learnt from Vioxx? BMJ. 2007;334(7585):120-3.
53. Goldman S. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20 Suppl. C:C40-4.
54. Trontell A. How the US Food and Drug Administration defines and detects adverse drug events. Curr Ther Res. 2001;62:641-9.
55. Wang HW, Hochberg AM, Pearson RK, et al. An experimental investigation of masking in the US FDA adverse event reporting system database. Drug Saf. 2010;33(12):1117-33.
56. Institute of Medicine. The future of drug safety: promoting and protecting the health of the public. Available from URL: http://www.iom.edu/ Reports/2006/The-Future-of-Drug-Safety-Promoting-and-Protecting-the-Health-of- the-Public.aspx. Accessed 20 Oct 2011.
57. Psaty BM, Burke SP. Protecting the health of the public: Institute of Medicine recommendations on drug safety. N Engl J Med. 2006;355(17):1753-5.
58. Hennessy S. Use of health care databases in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98(3):311-3.
59. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45(5):419-25.
60. Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects - advantages and disadvantages. Nat Clin Pract Rheumatol. 2007;3(12):725-32.
61. Kramarz P, France EK, Destefano F, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J. 2001;20(4):410-6.
62. US FDA. The FDA Sentinel initiative. Available from URL: http://www.fda.gov/Safety/FDAsSentinelInitiative. Accessed 12 Jul 2011.
63. Mini-Sentinel. Available from URL: http://mini-sentinel.org/ Accessed 15 Feb 2011.
64. Mini-Sentinel. Statistical methods development. Available from URL: http://mini-sentinel.org/methods/methods-development/default.aspx. Accessed 31 May 2012.
65. Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153(9):600-6.
66. Observational Medical Outcomes Partnership. Health outcomes of interest library. Available from URL: http://omop.fnih.org/HOI. Accessed 11 Nov 2011.
67. Observational Medical Outcomes Partnership. OMOP Cup 2010. Available from URL: http://omop.fnih.org/omopcup. Accessed 10 Oct 2011.
68. Observational Medical Outcomes Partnership. OMOP 2011 symposium presentations. Available from URL: http://omop.fnih.org/OMOP2011Symposium. Accessed 30 Mar 2012.
69. Exploring and Understanding Adverse Drug Reactions by Integrative Mining of Clinical records and Biomedical Knowledge. The EU-ADR Project. Available from URL: http://www.euadr-project.org. Accessed 12 Jul 2011.
70. Trifiro G, Pariente A, Coloma PM, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18(12):1176-84.
71. Platt R, Carnahan RM, Brown JS, et al. The US Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21(Suppl. 1):1-8.
72. Canadian Institutes of Health Research. About the drug safety effectiveness network. Available from URL: http://www.cihr-irsc.gc.ca/e/40269. html. Accessed Mar 2012.
73. Innovative Medicines Initiative. PROTECT project. Available from URL: http://www.imi-protect.eu/. Accessed Mar 2012.
74. Global Research in Paediatrics. Available from URL: http://www.grip- network.org/. Accessed 10 May 2012.
75. Kimura T, Matsushita Y, Yang YH, et al. Pharmacovigilance systems and databases in Korea, Japan, and Taiwan. Pharmacoepidemiol Drug Saf. 2011;20(12):1237-45.
76. Choi NK, Chang Y, Choi YK, et al. Signal detection of rosuvastatin compared to other statins: data-mining study using national health insurance claims database. Pharmacoepidemiol Drug Saf. 2010;19(3):238-46.
77. Braitstein P, Einterz RM, Sidle JE, et al. "Talkin' about a revolution": how electronic health records can facilitate the scale-up of HIV care and treatment and catalyze primary care in resource-constrained settings. J Acquir Immune Defic Syndr. 2009;52(Suppl. 1):S54-7.
78. Tierney WM, Achieng M, Baker E, et al. Experience implementing electronic health records in three East African countries. Stud Health Technol Inform. 2010;160(Pt 1):371-5.
79. Luhm KR, Cardoso MR, Waldman EA. Vaccination coverage among children under two years of age based on electronic immunization registry in Southern Brazil. Rev Saude Publica. 2011;45(1):90-8.
80. Bate A, Edwards IR, Edwards J, et al. Knowledge finding in IMS disease analyzer Mediplus UK database: effective data mining in longitudinal patient safety data. ISOP Annual Meeting: Pharmacovigilance - Current and Future Challenges, Dublin; 6-8 Oct 2004.
81. Curtis J, Cheng H, Delzell E, et al. Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example. Med Care. 2008;46(9):969-75.
82. Wang X, Hripcsak G, Markatou M, et al. Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. J Am Med Inform Assoc. 2009;16(3):328-37.
83. Svanstrom H, Callreus T, Hviid A. Temporal data mining for adverse events following immunization in nationwide Danish healthcare databases. Drug Saf. 2010;33(11):1015-25.
84. Velentgas P, Bohn RL, Brown JS, et al. A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study. Pharmacoepidemiol Drug Saf. 2008;17(12):1226-34.
85. Lieu TA, Kulldorff M, Davis RL, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care. 2007;45(10 Suppl. 2):S89-95.
86. Schuemie MJ. Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. Pharmacoepidemiol Drug Saf. 2011;20(3):292-9.
87. Noren GN, Hopstadius J, Bate A, et al. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Disc. 2010;20:361-87.
88. Observational Medical Outcomes Partnership. OMOP methods library. Available from URL: http://omop.fnih.org/Methods. Accessed 20 May 2012.
89. Zorych I, Madigan D, Ryan P, et al. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2011 [Epub ahead of print].
90. Coloma P, Schuemie MJ, Trifiro G, et al. Comparison of methods for drug safety signal detection using electronic healthcare record (EHR) databases: the added value of longitudinal, time-stamped patient information. Presented at the 27th international conference on pharmacoepidemiology and therapeutic risk management, Chicago; 14-17 Aug 2011.
91. Schuemie MJ, Coloma PM, Straatman H, et al. Using electronic healthcare records for drug safety signal detection: a comparative evaluation of statistical methods. Med Care. 2012;50:890-7.
92. Bauer-Mehren A, van Mullingen EM, Avillach P, et al. Automatic filtering and substantiation of drug safety signals. PLoS Comput Biol. 2012;8(4):e1002457.
93. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323-37.
94. Hsia DC, Krushat WM, Fagan AB, et al. Accuracy of diagnostic coding for Medicare patients under the prospective-payment system. N Engl J Med. 1988;318(6):352-5.
95. Coloma PM, Trifiro G, Schuemie MJ, et al. Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf. 2012;21:611-21.
96. Daily Med. Trovafloxacin drug label. Available from URL: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=442&CFID= 66575927&CFTOKEN=a17d753a0754a3fb-24987D34-D80B-CD9C- 39F668DB8C41A045&jsessionid=ca30e46b22b0112063a4. Accessed 13 Jul 2011.
97. Daily Med. Rosiglitazone drug label. Available from URL: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=38243. Accessed 13 Jul 2011.
98. European Medicines Agency. Tysabri (natalizumab). Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000603/human-med-001119.jsp&murl=menus/medicines/medicines.jsp&mid= WC0b01ac058001d124. Accessed 13 Jul 2011.
99. MHRA. Dopamine agonists for Parkinson's disease. Available from URL: http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/ Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/ DopamineagonistsforParkinson146sdisease/index.htm. Accessed 13 Jul 2011.
100. European Commission. A guideline on summary of product characteristics. Available from URL: http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc- guideline-rev2-en.pdf. Accessed 20 Apr 2012.
101. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ. 2003;327(7425):1222-5.
102. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies D, editor. Textbook of adverse drug reactions. 3rd ed. Oxford: Oxford University Press; 1985.
103. Edwards IR. What are the real lessons from Vioxx? Drug Saf. 2005;28(8):651-8.
104. Fung M, Thornton A, Mybeck K, et al. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets - 1960 to 1999. Drug Inf J. 2001;35:293-317.
105. Trifiro G, Patadia V, Schuemie MJ, et al. EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection. Stud Health Technol Inform. 2011;166:25-30.
106. Tatonetti NP, Fernald GH, Altman RB. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc. 2012;19(1):79-85.
107. Meyboom RH, Lindquist M, Egberts AC, et al. Signal selection and follow-up in pharmacovigilance. Drug Saf. 2002;25(6):459-65.